Get this report today!
Table of Contents
Datamonitor's Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in Brazil, Hungary, Mexico, Poland, South Africa, and Taiwan. The report includes easily comparable data on market value, volume, segmentation and market share for the advanced emerging markets pharmaceuticals markets, plus full five-year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from Brazil, Hungary, Mexico, Poland, South Africa and Taiwan, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
The advanced emerging market countries contributed $31.0 billion to the global pharmaceuticals industry in 2006, with a compound annual growth rate (CAGR) of 8.2% between 2006 and 2010 bringing this contribution to $42.5billion.
These countries are expected to reach a value of $73.1 billion in 2015, with a CAGR of 11.5% over the 2010–15 period.
Brazil holds the major share of the pharmaceuticals industry. In 2010, it accounted for 36% of the market
Among the advanced emerging market nations, Brazil is the leading country in the pharmaceuticals industry, with market revenues of $15.3 billion in 2010.
Brazil is expected to lead the pharmaceuticals industry in the advance emerging market nations, with a value of $34.4 in 2015
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
In this report, the pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2009 annual average exchange rates.
Talk to Jordan
+1 917 267 7886
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, ...
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute o ...
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked ...
... Complexities, and so on). Within the cro market, the largest segment was that of drug discovery. Based on various analyses, the report also anticipates that the market for clinical data management services ...
... Hg introduces new recommendations designed to promote safer use of angiotensin converting enzyme inhibitors (aceis) and angiotensin receptor blockers (arbs) first-line and later-line treatment should now ...
... Learn/confirm and predict phase vi registering and labeling (maa) uncertainty confident and drug and disease paediatric strategy & investigation plan scientific advice clinical trial ...
Reportlinker.com © Copyright 2014. All rights reserved.